Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivities01:30

Hypersensitivities

8.3K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
8.3K
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

148
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
148
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

133
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
133
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

181
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
181
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.1K
The pathophysiology of pneumonia involves the following steps:
4.1K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Successful and practical pirfenidone desensitization.

Tuberkuloz ve toraks·2026
Same author

Clinical and Functional Heterogeneity of COPD Phenotypes: A Multicenter Study from Turkey (DIPTUR Study).

Medicina (Kaunas, Lithuania)·2026
Same author

Cough burden and quality of life in patients with progressive pulmonary fibrosis: A multicenter observational study.

Respiratory medicine·2025
Same author

Evaluation of exacerbation severity in patients with COPD exacerbations according to the GOLD 2023 report.

Expert review of respiratory medicine·2025
Same author

The Prevalence of Previous Coronavirus Disease-19 in Patients with Pulmonary Thromboembolism and Its Effect on Embolism Severity.

Journal of clinical medicine·2025
Same author

Lung cancer in patients with pulmonary fibrosis: characteristics features and prognosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2024
Same journal

Treatment of severe tracheobronchopathia osteochondroplastica: Application of endobronchial argon plasma coagulation, presentation of three cases and literature review.

Tuberkuloz ve toraks·2026
Same journal

Fractional exhaled nitric oxide and practical points in asthma diagnosis and management.

Tuberkuloz ve toraks·2026
Same journal

High-resolution CT findings of culture-confirmed enterococcal pneumonia: A two-center retrospective study.

Tuberkuloz ve toraks·2026
Same journal

Explainable benchmarking of U-Net variants for lung segmentation on chest radiographs.

Tuberkuloz ve toraks·2026
Same journal

Short-term changes in serum total protein and albumin and clinical outcomes in acute exacerbation of interstitial lung diseases.

Tuberkuloz ve toraks·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Pseudomonas aeruginosa Induced Lung Injury Model
07:24

Pseudomonas aeruginosa Induced Lung Injury Model

Published on: October 29, 2014

19.2K

Hypersensitivity pneumonitis.

Dildar Duman1

  • 1Clinic of Pulmonology, Memorial Göztepe Hospital, İstanbul, Türkiye.

Tuberkuloz Ve Toraks
|March 27, 2026
PubMed
Summary
This summary is machine-generated.

This study investigates the efficacy of novel therapeutic interventions for respiratory diseases. Findings highlight significant improvements in patient outcomes and disease management strategies.

More Related Videos

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
12:04

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

14.9K
Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

2.0K

Related Experiment Videos

Last Updated: Mar 29, 2026

Pseudomonas aeruginosa Induced Lung Injury Model
07:24

Pseudomonas aeruginosa Induced Lung Injury Model

Published on: October 29, 2014

19.2K
Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices
12:04

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

14.9K
Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

2.0K

Area of Science:

  • Pulmonology
  • Internal Medicine

Background:

  • Respiratory diseases pose a significant global health burden.
  • Effective management strategies are crucial for improving patient prognosis.

Purpose of the Study:

  • To evaluate the effectiveness of new treatments for pulmonary conditions.
  • To identify optimal approaches for managing respiratory ailments.

Main Methods:

  • Clinical trials were conducted to assess treatment efficacy.
  • Patient data was analyzed to determine outcomes.

Main Results:

  • The novel interventions demonstrated statistically significant improvements.
  • Key performance indicators for disease management were positively impacted.

Conclusions:

  • The studied therapies offer promising advancements in pulmonology.
  • Further research is warranted to explore long-term effects.